PABPC1 gene knockout MDCK cell line as well as construction method and application thereof

By using CRISPR/Cas9 technology to knock out the PABPC1 gene in MDCK cells, the PABPC1 knockout cell line was constructed, which solved the problem of insufficient replication rate of avian influenza virus in the MDCK cell line, significantly improved the viral replication rate and vaccine production efficiency, and reduced costs .

CN118931900APending Publication Date: 2024-11-12INST OF ANIMAL SCI & VETERINARY MEDICINE SHANDONG ACADEMY OF AGRI SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410967105.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-18
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the production of existing cellular matrix influenza vaccines, the MDCK cell lines have insufficient replication speed in avian influenza viruses, which affects vaccine production efficiency and cost. There are no reports on knocking out the PABPC1 gene sequence using the CRISPR/Cas9 system.

Method used

Design a dual gRNA combination and CRISPR/Cas9 system that targets the PABPC1 gene. By knocking out the PABPC1 gene in MDCK cells, the MDCK cell line with PABPC1 gene knockout was constructed, and the target was designed upstream and downstream of exon2 and exon6 of PABPC1 using CRISPR/Cas9 technology. 5065 bases were successfully knocked out, increasing the replication rate of avian influenza viruses.

Benefits of technology

Through PABPC1 gene knockout, the replication rate of avian influenza viruses has been significantly accelerated, and it has no significant impact on cell growth rate, improving the production efficiency of influenza vaccines and reducing production costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118931900A_ABST
    Figure CN118931900A_ABST
Patent Text Reader

Abstract

The invention discloses a PABPC1 gene knockout MDCK (Madin-Darby Canine Kidney) cell line as well as a construction method and application thereof, and belongs to the technical field of gene engineering. According to the present invention, the CRISPR / Cas9 technology is adopted, the upstream and the downstream of the exon2 and the exon6 of the PABPC1 gene are respectively provided with one target spot, and the gRNA-A1 and the gRNA-A2 are adopted to knock out 5065 bases of the PABPC1 gene in the avian influenza vaccine production cell line MDCK so as to successfully construct the PABPC1 gene knockout MDCK cell line; in the PABPC1 knockout MDCK cell line, the avian influenza virus replication rate is obviously accelerated, and the cell growth rate is not obviously influenced after the PABPC1 is knocked out. The invention plays an important role in improving the production efficiency of the avian influenza vaccine and reducing the production cost of the vaccine.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of genetic engineering, and in particular to a PABPC1 gene knockout MDCK cell line and a construction method and application thereof. Background Art

[0002] Avian influenza (AI) is a viral infectious disease of poultry caused by influenza A virus. AIV is a single-stranded negative RNA virus, and its genome consists of 8 single-stranded negative RNA. According to the antigenic differences of the viral surface glycoprotein (hemagglutinin, HA) and neuraminidase (neuraminidase, NA), avian influenza virus (AIV) can be divided into 18 HA subtypes and 11 NA subtypes, and there are significant differences between different subtypes; according to the pathogenicity of AIV to SPF chickens, it is divided into two types: highly pathogenic AIV (Highly pathogenic avianinfluenza, HPAIV) and low pathogenic AIV (Low pathogenic avian influenza, LPAIV). After poultry is infected with AIV, symptoms can manifest in various forms such as non-overt infection, subclinical infection, or mild respiratory disease, reduced egg production, and even acute systemic lethal disease. At present, the prevention and control of the disease is mainly based on vaccine immunization, and traditional inactivated vaccines still dominate the market. There are currently two main methods for producing avian influenza vaccines, one is the traditional chicken embryo matrix vaccine, and the other is the emerging cell matrix vaccine. Compared with the traditional chicken embryo process, the influenza vaccine produced by cell matrix has many advantages, such as a stricter sterile environment, easier to expand the production scale, more flexibility, fewer sources of allergies, etc. It has the potential to replace the current chicken embryo process and has an immeasurable development prospect in the future poultry market. However, cell matrix influenza vaccines also face challenges in production, such as how to breed cell lines with higher antigen production.

[0003] In the production of cell-based influenza vaccines, the most widely used cells are canine kidney cells (MDCK). The first influenza vaccine produced using animal cell culture technology was produced by MDCK cells, which was the trivalent inactivated influenza vaccine Optaflu produced by Novartis in Switzerland using MDCK-33016PF cells in 2007. Since then, many commercially available influenza vaccines have been produced using MDCK cells as a medium. Therefore, domestic and foreign scholars have also used MDCK cell lines as a culture system for cell-based vaccines of different subtypes of AIV, and have attempted to increase the replication rate of the virus by modifying the receptors of the cell line.

[0004] CRISPR / Cas9 technology is a new gene editing technology that has developed rapidly in recent years and can be used in mammalian cells. It has very good application prospects in many fields. Using the new generation of Crispr / Cas9 gene editing technology to knock out restriction factors of viral growth and knock in key replication-related genes is expected to provide alternative cell lines for the production of influenza and other vaccines, laying the foundation for large-scale production of influenza vaccines and promoting the upgrading of the influenza vaccine industry. At present, there are no reports on the use of CRISPR / Cas9 system to knock out the PABPC1 gene sequence in MDCK cells. Summary of the invention

[0005] In view of the above-mentioned prior art, the object of the present invention is to provide a PABPC1 gene knockout MDCK cell line and a construction method and application thereof.

[0006] To achieve the above object, the present invention adopts the following technical solution:

[0007] In a first aspect of the present invention, a dual gRNA combination targeting the PABPC1 gene is provided, comprising a gRNA-A1 targeting the second exon of the PABPC1 gene and a gRNA-A2 targeting the sixth exon of the PABPC1 gene;

[0008] The nucleotide sequence of gRNA-A1 is shown in SEQ ID NO: 1; the nucleotide sequence of gRNA-A2 is shown in SEQ ID NO: 2.

[0009] The second aspect of the present invention provides a gene knockout vector, which is constructed by recombining the double gRNA combination into an expression vector.

[0010] The third aspect of the present invention provides a CRISPR / Cas9 system for specifically targeting and knocking out the PABPC1 gene, comprising: the dual gRNA combination targeting the PABPC1 gene and the Cas9 protein.

[0011] The fourth aspect of the present invention provides the use of the dual gRNA combination, the gene knockout vector or the CRISPR / Cas9 system in PABPC1 gene editing.

[0012] The fifth aspect of the present invention provides the use of the dual gRNA combination, the gene knockout vector or the CRISPR / Cas9 system in constructing a PABPC1 knockout model.

[0013] In a sixth aspect, the present invention provides the use of the dual gRNA combination, the gene knockout vector or the CRISPR / Cas9 system in constructing a PABPC1 gene mutation library.

[0014] In a seventh aspect, the present invention provides a method for constructing a PABPC1 gene knockout cell line, which uses CRISPER / Cas9 technology to construct a PABPC1 gene knockout cell line, and the method uses SEQ ID No: 13 in the coding sequence of the PABPC1 gene as the target sequence.

[0015] Furthermore, the PABPC1 gene knockout cell line is an MDCK cell line.

[0016] Beneficial effects of the present invention:

[0017] (1) The present invention utilizes CRISPR / Cas9 technology, designs one target site each at the upstream and downstream of exon2 and exon6 of the PABPC1 gene, and uses gRNA-A1 and gRNA-A2 to knock out 5065 bases of the PABPC1 gene in the MDCK cell line used for avian influenza vaccine production, thereby successfully constructing an MDCK cell line with a PABPC1 gene knockout.

[0018] (2) The present invention uses dual gRNAs instead of a single gRNA with a poorer effect for gene knockout. In the MDCK cell line with PABPC1 knockout, the replication rate of avian influenza virus is significantly accelerated, and PABPC1 knockout has no significant effect on cell growth rate. The present invention plays an important role in improving the production efficiency of avian influenza vaccines and reducing the cost of vaccine production. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Identification of PABPC1 knockout cell lines. Figure 1 A in the middle is the location of the target gRNA and identification primer in the genome. Figure 1 Middle B, Figure 1 Middle C and Figure 1 D in the figure are the PCR identification results of wild-type PABPC1 (WT) and knockout cell lines (1, 2) in MDCK cells using identification primers PR1-F / R, PR2-F / R and PR3-F / R, respectively, where M is a protein marker. Figure 1 Middle E is the sequencing peak graph of the deleted PABPC1 near the deletion position in the MDCK knockout cell line, and the red arrow indicates the knockout position. Figure 1 Middle F is the Western blot detection of the control cell line and the PABPC1 knockout cell line, in which β-Actin was used as an internal reference control.

[0020] Figure 2 The viral replication level of viral RNA in the PABPC1 knockout cell line (PABPC1-KO-4E9) and the control cell line (Control) after avian influenza virus infection was measured.

[0021] Figure 3 Cell morphology and cell viability assay of PABPC1 knockout cell line (PABPC1-KO-4E9) and control cell line (Control). Figure 3 Middle A shows the cell morphology of the PABPC1 knockout cell line after 48 hours of culture. Figure 3 Figure B shows the cell viability assay of PABPC1 knockout cell lines and control cell lines. DETAILED DESCRIPTION

[0022] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0023] In order to enable those skilled in the art to more clearly understand the technical solution of the present application, the technical solution of the present application will be described in detail below in conjunction with specific embodiments.

[0024] The test materials used in the embodiments of the present invention that are not specifically described are all conventional test materials in the art and can be purchased through commercial channels. The avian influenza virus used in the present invention is the H9N2 AIV G57 genotype strain CK / SD / 3424 / 16, and the cell line used is the adherent culture type MDCK cell line, all of which are preserved by the Animal Husbandry and Veterinary Research Institute of Shandong Academy of Agricultural Sciences. The cells were cultured in a 5% CO2 incubator at a culture temperature of 37°C, and the culture medium used was a DMEM culture medium supplemented with 10% fetal bovine serum and 1% antibiotics (penicillin-streptomycin).

[0025] Example 1: Construction of PABPC1 knockout MDCK cell line using CRIPSR / Cas9 technology

[0026] According to the PABPC1 gene sequence of Canis lupus in NCBI (NCBI number NM_001031597.2), it is planned to knock out the sequence with the start and end bases located at 3816bp-8880bp in the gene, with a length of 5065bp. The specific nucleotides of the target sequence (SEQ ID NO: 13) are as follows:

[0027]

[0028] Design one target site each in the upstream and downstream of exon2 and exon6 of PABPC1, namely gRNA-A1 and gRNA-A2:

[0029] gRNA-A1:CAGCAGTCTTAAGTTTAAAGAGG (SEQ ID NO: 1);

[0030] gRNA-A2: GTAACTGGAGGGGTTTGTGAGGGG (SEQ ID NO: 2).

[0031] According to the design plan, gRNA for knocking out PABPC1 was selected ( Figure 1 A) and Cas9 protein, the two were incubated to form an RNP complex, and MDCK cells in logarithmic phase growth with good resuspending state were selected as the suspension, and Neon TM The cells were electroporated using a transfection instrument (Cat#MPK5000), and the EGFP control group was electroporated under the same parameters.

[0032] After electroporation, transfer each group of cells to the corresponding culture vessels and place them in an incubator for culture. After 24 hours, observe the cell status and judge the electroporation efficiency based on the situation of the EGFP control group. Digest the cell count and inoculate the single clone. During this period, observe the growth status of the clone and change the medium in time. When the clone grows to a sufficient number, perform PCR after backup to preliminarily judge the single clone cells with successful knockout ( Figure 1 Middle B, Figure 1 Middle C and Figure 1 Middle D), identification of gRNA targeting sites and knockout bands.

[0033] Primer pairs used to amplify exon2:

[0034] PR1-F: 5'-AGGAGTCACTGAAATCCCCCTG-3' (SEQ ID NO: 3);

[0035] PR1-R: 5'-TCAGTCTCCTAGCCCGAGTTT-3' (SEQ ID NO: 4).

[0036] Primer pairs used to amplify exon6:

[0037] PR2-F: 5'-CTGATGGGTCCATCTTTAGC-3' (SEQ ID NO: 5);

[0038] PR2-R: 5'-AAACACTCCACACATTACTGTGAAA-3' (SEQ ID NO: 6).

[0039] Primer pair used to amplify exon2-exon6:

[0040] PR3-F: 5'-CTGATGGGTCCATCTTTAGC-3' (SEQ ID NO: 7);

[0041] PR3-R: 5'-AAACACTCCACACATTACTGTGAAA-3' (SEQ ID NO: 8).

[0042] The knockout cell line was initially identified based on the PCR amplification results and sent for sequencing. The sequencing results were compared with Snapgene software to determine the knockout cell line. The monoclonal cell line PABPC1-KO-4E9 had a 5065-base deletion at the Cas9-predetermined cutting position in the PABPC1 gene ( Figure 1 Middle E), the quality of the sequencing peaks near the mutation site is very high, indicating that the sequencing results are reliable.

[0043] To prove the successful knockout of PABPC1 gene at the protein level, normal cultured cells of wild-type cell line (Control) and PABPC1 knockout cell line (PABPC1-KO-4E9) were collected, and the protein expression level of endogenous PABPC1 was detected by Western blot using PABPC1 antibody (CST, 987561), and the internal control was β-Actin.

[0044] Results Figure 1 In F, the expression of PABPC1 can be detected in the control cell line, while in the knockout cell line, the expression of PABPC1 protein is significantly decreased, thus proving that the heterozygous MDCK cell line with PABPC1 gene knockout was successfully obtained.

[0045] Example 2: Replication rate of avian influenza virus in PABPC1 knockout cell line

[0046] In order to evaluate the replication rate of avian influenza virus in PABPC1 knockout cell lines, RT-qPCR was used to detect the relative expression of viral RNA. When the PABPC1 knockout MDCK cell line (PABPC1-KO-4E9) and the wild-type cell line were cultured to about 80% confluence in a 24-well cell culture plate, the culture medium was aspirated, 2 mL PBS was added to wash the cells twice, and the PBS was aspirated cleanly. The PABPC1-KO-4E9 cell line and the wild-type cell line were randomly divided into two parts. Avian influenza virus diluted to MOI = 0.1 was added to one PABPC1-KO-4E9 cell line and one wild-type cell line, and 0.5 mL DMEM was added to another PABPC1-KO-4E9 cell line and another wild-type cell line. The above four groups of cells were incubated in an incubator for 2 h, the virus solution was aspirated, 1 mL PBS was added to wash the cells twice, and the PBS was aspirated cleanly, and 0.5 mL DMEM culture medium containing TPCK-trypsin was added. On the third day after infection, cell samples were collected and RT-qPCR was used to quantify the viral M gene RNA, determine the proliferation of avian influenza virus, and evaluate the effect of PABPC1 knockout on the replication rate of avian influenza virus. β-Actin was used as an internal reference gene to quantify the relative expression level of M.

[0047] In the above process, the collected cell samples were used to extract total RNA using the SPARKeasy tissue / cell RNA rapid extraction kit (Shandong Sikejie Biotechnology Co., Ltd.), and after the concentration was determined, RT-qPCR was performed using Taq Pro SYBR qPCR Master Mix (Nanjing Novogene Biotechnology Co., Ltd.). The primer pairs used are as follows:

[0048] The primer pairs for the M gene are:

[0049] M-qF: 5'-GGCGACTACTACCAACCCACTA-3' (SEQ ID NO: 9);

[0050] M-qR: 5'-GCCATCTGCTCCATAGCCTT-3' (SEQ ID NO: 10).

[0051] The internal reference primer pair is:

[0052] β-actin-qF: 5'-ATGAAGCCCAGAGCAAAAGA-3' (SEQ ID NO: 11);

[0053] β-actin-qR: 5'-GGGGTGTTGAAGGTCTCAAA-3' (SEQ ID NO: 12).

[0054] The results are as follows Figure 2 As shown, after avian influenza virus infection, the replication level of viral RNA in the PABPC1 knockout cell line (PABPC1-KO-4E9) was significantly higher than that in the control cell line (Control), indicating that PABPC1 knockout cells can significantly accelerate the replication rate of avian influenza virus.

[0055] Example 3: Determination of growth rate of PABPC1 knockout cell line

[0056] The PABPC1 knockout cells (PABPC1-KO-49E) obtained in Example 1 were digested and counted as the experimental group and the wild-type cell line (Control) as the control group, and 10,000 cells per well were inoculated into a 96-well plate and placed in a cell culture incubator for normal culture for 48 hours. 10 μL of CCK-8 solution (cell viability was determined using the CCK8 method) was added to the culture medium of each well, and the culture was continued in the incubator for 1 hour, and the absorbance at 450 nm was measured on an Epoch2 microplate reader (BioTek).

[0057] The results are as follows Figure 3 As shown, the PABPC1 knockout cell line has good cell growth ( Figure 3 There was no significant difference in growth rate compared with the wild-type cell line as the control group ( Figure 3 (B).

[0058] The above description is only the preferred embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. A dual gRNA combination targeting the PABPC1 gene, characterized in that: including gRNA-A1 targeting the second exon of the PABPC1 gene and gRNA-A2 targeting the sixth exon of the PABPC1 gene; The nucleotide sequence of gRNA-A1 is shown in SEQ ID NO: 1; the nucleotide sequence of gRNA-A2 is shown in SEQ ID NO:

2.

2. A gene knockout vector, characterized in that: The gene knockout vector is constructed by recombining the dual gRNA combination described in claim 1 into an expression vector.

3. A CRISPR / Cas9 system for specifically targeting and knocking out the PABPC1 gene, comprising: The dual gRNA combination targeting the PABPC1 gene and the Cas9 protein as described in claim 1.

4. Use of the dual gRNA combination of claim 1, the gene knockout vector of claim 2, or the CRISPR / Cas9 system of claim 3 in PABPC1 gene editing.

5. Use of the dual gRNA combination of claim 1, the gene knockout vector of claim 2, or the CRISPR / Cas9 system of claim 3 in constructing a PABPC1 knockout model.

6. Use of the dual gRNA combination of claim 1, the gene knockout vector of claim 2, or the CRISPR / Cas9 system of claim 3 in constructing a PABPC1 gene mutation library.

7. A method for constructing a PABPC1 gene knockout cell line, characterized in that: The CRISPER / Cas9 technology is used to construct a PABPC1 gene knockout cell line, wherein SEQ ID No: 13 in the coding sequence of the PABPC1 gene is used as the target sequence.

8. The method for constructing a PABPC1 gene knockout cell line according to claim 7, characterized in that: The PABPC1 gene knockout cell line is an MDCK cell line.